Direct answer: A cosmetic peptide raw-material dossier should match the exact ingredient identity to its INCI name, composition, impurity profile and intended market. A CosIng entry is informative; it is not an approval, and finished-product safety duties remain with the responsible market actor.
Technical editorial review: 22 October 2026. Confirm current standards, market rules and batch records before purchase.
Separate the ingredient name from market authorization
A cosmetic ingredient may appear under a commercial name, a technical sequence name and a common ingredient name used for labeling. The buyer should map those names to one defined material before building a formula or artwork. The European Commission’s CosIng database provides information about cosmetic substances and ingredient names, including searchable CAS and other identifiers. The Commission explicitly says the database is informative and that appearance of an INCI name does not mean the ingredient is approved for cosmetic use. EU market decisions must be checked against Regulation (EC) No 1223/2009 and its annexes, together with the actual product and claim. A supplier can provide identity, composition and quality records, but the brand or responsible person must assess the finished product in its target market. A catalog name should therefore never be presented as a legal clearance or as evidence of clinical benefit.
Identity mapping for a cosmetic peptide
- Commercial name and exact raw-material composition
- INCI or other applicable ingredient name
- CAS or other identifier where relevant
- Peptide form, counterion, carrier and declared excipients
- Destination-market and finished-product use category
Build a dossier that a formulator can actually evaluate
The useful raw-material dossier connects a current specification to the material the formulator will receive. It should state identity, composition, relevant impurities, recommended handling, packaging and batch-traceable COA data. If the ingredient is supplied as a solution or blend, ask for the concentration and every carrier or preservative rather than treating the peptide name as the whole formula. The formulator also needs compatibility and stability information appropriate to the planned finished product. Test methods and results should be distinguished from marketing copy, and any gap should be recorded as an open item. For the EU, final-product safety assessment, labeling and other obligations are determined under the applicable cosmetic framework. Supplier data are inputs to that work, not a substitute for it. The cosmetic peptide category is a discovery list; request the current dossier for any item under consideration before selecting claims or label text.
Raw-material file contents
- Signed specification and compositional statement
- Current lot COA with named methods
- Relevant safety and stability information
- Packaging, storage and change-notification terms
US documentation: safety substantiation is product-specific
In the United States, FDA describes obligations under the Modernization of Cosmetics Regulation Act of 2022, including facility registration and product listing provisions subject to applicable exemptions, as well as safety substantiation records for cosmetic products. FDA also states that it does not prescribe a universal test list for every cosmetic ingredient or product. That means a peptide supplier’s HPLC result or ingredient brochure cannot establish the safety of every finished serum, film or patch. The responsible company needs to consider the complete formulation, exposure, packaging, intended use and evidence supporting its product. Cross-border procurement should ask which party prepares raw-material data, finished-product safety work, label review and market filings. If the project moves from a cosmetic raw material to a product with drug claims, the classification and requirements change. Use the Private Label and Contact pages to scope those responsibilities before artwork or batch release.
Responsibility matrix for an OEM inquiry
- Supplier: verified raw-material identity and batch documentation
- Brand or responsible person: finished-product safety and claims
- Both parties: specifications, artwork, change control and traceability
Frequently asked questions
Does an INCI name mean an ingredient is approved in the EU?
No. The European Commission says CosIng is informative and an INCI listing is not an approval.
Does a peptide COA prove a finished cosmetic is safe?
No. It is one input to a finished-product assessment that also considers formula, exposure and intended use.
Who owns US cosmetic product safety records?
FDA describes safety substantiation duties for the responsible person; supplier documents support but do not replace that work.
References and scope
These primary sources define the cited concepts. Regulatory guidelines apply only within their stated scope; this article provides buyer questions and does not certify a particular material or lot.
- European Commission CosIng ingredient database
- FDA: Modernization of Cosmetics Regulation Act
- FDA: Product Testing of Cosmetics
Related: product catalog · quality review · all resources · request a project quote.